{"product_id":"retatrutide-20-mg","title":"Retatrutide","description":"\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:0 0 .4em;font-family:inherit;\"\u003eWhat it is\u003c\/p\u003e\n\u003cp style=\"font-size:1.12em;line-height:1.7;margin:0 0 1em;\"\u003eThe most potent metabolic peptide in the literature today. It acts \u003cstrong\u003eon three switches at once\u003c\/strong\u003e for appetite and energy expenditure, instead of on just one like earlier-generation compounds.\u003c\/p\u003e\n\u003cp style=\"font-size:1.02em;line-height:1.7;margin:0 0 1.2em;color:#374151;\"\u003eYour body has several hormones that tell the brain “that's enough, stop eating.” Retatrutide mimics three of them simultaneously. The first two reduce hunger; the third also makes the body burn more. That is why the published figures are higher than those of any other compound in its family.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat it is used for\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Research on body weight and appetite control\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Body recomposition studies: how much fat is lost and how much muscle is preserved\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Energy expenditure: the branch that sets it apart from the rest\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Fatty liver and blood sugar control\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it is used\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:12px;margin:0 0 1.4em;flex-wrap:wrap;\"\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eCycle\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eContinuous until target\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eBreak\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eNot required\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eRoute\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eWeekly subcutaneous\u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eLyophilized powder. It is reconstituted with bacteriostatic water, swirled without shaking until dissolved, and stored between 2 and 8 °C. In the literature it is administered once a week, always with gradual dose escalation: increasing slowly is what reduces digestive discomfort \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat has been observed\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;color:#6b7280;font-size:.95em;\"\u003eResults described in the published scientific literature. They are not directions for use or health recommendations.\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  In the phase 2 trial (338 adults, 48 weeks), the 12 mg dose produced a mean body weight reduction of \u003cstrong\u003e24.2%\u003c\/strong\u003e, versus 2.1% with placebo \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  At 8 mg, 100% of participants lost at least 5% of their weight, 91% at least 10%, and 75% at least 15% \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  A phase 2a trial in metabolic fatty liver disease described significant reductions in liver fat content \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Digestive effects were the most frequent: they were dose-dependent, mostly mild or moderate, and were attenuated by starting with a lower initial dose \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  A dose-dependent increase in heart rate was observed, peaking at 24 weeks and declining thereafter \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it works\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eGIP \/ GLP-1 \/ glucagon triple agonism\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eRetatrutide (LY-3437943) acts as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e. The first two branches reduce intake centrally and slow gastric emptying.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eThe glucagon branch\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThis is what sets it apart from dual agonists. Signaling through the glucagon receptor is associated with increased energy expenditure and mobilization of liver fat, so energy balance is addressed from both sides: less in and more out \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eClinical development\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eIt has completed phase 2 in obesity and in metabolic dysfunction-associated steatotic liver disease, and is in registrational phase 3 in obesity, sleep apnea and knee osteoarthritis, as well as type 2 diabetes \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eState of the evidence\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eClinical and top-tier.\u003c\/strong\u003e The data come from randomized, placebo-controlled clinical trials published in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e, \u003cem\u003eNature Medicine\u003c\/em\u003e and \u003cem\u003eThe Lancet\u003c\/em\u003e \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e. One distinction is worth keeping in mind: those clinical trials were conducted with a pharmaceutical product in patients and under medical supervision. What we offer here is reference material for research, not an approved medicine.\u003c\/p\u003e\n\n\u003cp style=\"margin:1.6em 0 0;padding:12px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e⚠️ Product intended exclusively for \u003cstrong\u003eresearch and laboratory use\u003c\/strong\u003e. Not for human or veterinary consumption.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eReferences\u003c\/p\u003e\n\u003col style=\"margin:0;padding-left:1.4em;font-size:.86em;color:#6b7280;line-height:1.7;\"\u003e\n  \u003cli\u003eJastreboff AM, et al. \u003cem\u003eTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.\u003c\/em\u003e N Engl J Med, 2023. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 37366315\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eSanyal AJ, et al. \u003cem\u003eTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.\u003c\/em\u003e Nat Med, 2024. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 38858523\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eBajaj HS, et al. \u003cem\u003eEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial.\u003c\/em\u003e Lancet, 2026. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42250575\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 42250575\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eKatsi V, et al. \u003cem\u003eRetatrutide — A Game Changer in Obesity Pharmacotherapy.\u003c\/em\u003e Biomolecules, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40563436\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40563436\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"PeptidoBioGenetic","offers":[{"title":"15 mg","offer_id":54603479646537,"sku":"RT15","price":177.76,"currency_code":"EUR","in_stock":true},{"title":"20 mg","offer_id":54603479679305,"sku":"RT20","price":234.35,"currency_code":"EUR","in_stock":true},{"title":"30 mg","offer_id":54760619049289,"sku":"RT30","price":360.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1016\/7507\/3865\/files\/principal-sin-fondo-removebg-preview.png?v=1782817358","url":"https:\/\/www.peptidobiogenetic.com\/en-us\/products\/retatrutide-20-mg","provider":"PeptidoBioGenetic","version":"1.0","type":"link"}